2023 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF):
- 6 January 2023: Silent period
- 3 February 2023: Annual report 2022
- 23 March 2023 at 4.00p.m.:
Annual General Meeting to be held at
ALK
Bøge Allé 1
2970 Hørsholm, Denmark
Written requests to have specific business transacted at the AGM will be included in the agenda if received by the company on 8 February 2023 at the latest (may be e-mailed to investor@alk.net)
- 11 April 2023: Silent period
- 9 May 2023: Three-month interim report (Q1) 2023
- 27 July 2023: Silent period
- 24 August 2023: Six-month interim report (Q2) 2023
- 18 October 2023: Silent period
- 15 November 2023: Nine-month interim report (Q3) 2023
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment